IL3RA and acute myeloid leukemia: A first-in-human study evaluated the safety and the clinical efficacy of JNJ-63709178, a CD123/CD3-targeting antibody, in a group of relapsed/refractory AML patients; either intravenous or subcutaneous administration of the antibody was evaluated [102].